Replies to post #31431 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

I hope you are right. I want to see the company sold for as high a price possible but I'd like to see it come now. There were a lot of missteps and pure greed from DO over the last four years at the expense of investors. We will see if I'm right in thinking our tutes may want to see a sale now given how terrible stock performance has been and it's a perfect time now that we are submitting for EU approval and leadership transition. Dan may have been pushed out to pave the way for a sale that he was against.

[hovacre]

My estimate is why I'd much prefer to see ADXS advance in the clinical pathway than get bought out. If they will be successful, there's a lot more value to be realized than we're currently seeing.

So I do not support a 500-750 million buyout.

[fbg0316]

Excel, I personally think realistically if the ADXS Board and Lombardo are good, they can sell the company now for around $1 billion ($25 share price). ADXS has some $900 million in potential milestones via Amgen and Sellas (albeit far from certain payments in the future). Also the pipeline is positioned nicely, with one Phase 3 currently in play for cervical, EU application pending, a combo PSA with Merck, a combo DUAL with Bristol, Phase I in HER 2, and potential licensing deals for all the above and HOT. The company is in a good position to sell now, and I think $1 billion is fair for investors and gets the platform into the hands of a larger company to deliver more efficiently and faster, and importantly transfer the late stage trial risk onto them. Why would our investor base who recapitalized the company pumping some $200+ million and are down nearly 50% because of a poor business strategy and greedy CEO want to start over and wait out another four years with a new CEO especially when the stakes for execution missteps are that much more critical during our current Phase 3 clinical stage. I think it's in all of our interests to sell the company now.